After the reported birth of CRISPRed babies in China, experts want to take time to consider the scientific, social, ethical, and philosophical consequences of editing heritable human DNA.

A mouse study details a method called VIVO that predicts the accuracy of any guide RNA.

The DNA-cutting enzyme used in the technique is not as precisely targeted as scientists had thought, and investors take notice.

Last year, researchers claimed the gene-editing method had accuracy issues, but a new whole-genome sequencing analysis by the same team finds otherwise.

A new study finds that more than 200 human-targeted, non-antibiotic drugs inhibit the growth of bacterial species that make up part of the human microbiome.

Researchers have developed a variety of techniques to detect when CRISPR misses the mark.

A tweaked Cas9 nuclease reduces off-target effects to levels below that of previous versions of the enzyme.

Slight sequence differences confound target sites in precision genome-editing, a study shows.

A study of off-target effects that sparked fear among investors of genome-editing companies receives methodological criticisms.